Umbrella therapy
Reading File
Searching the Web
umbrella therapy clinical trials oncology definition
Finding Sources
Searching PubMed
"umbrella trial" oncology precision medicine
Reading File
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC9596938
Here is a thorough overview of Umbrella Therapy / Umbrella Trials:
Umbrella Trials (Umbrella Therapy)
What Is It?
An umbrella trial is a type of master protocol clinical trial that tests multiple targeted therapies within a single disease type, stratifying patients into sub-trials based on their tumor's molecular (biomarker) profile. It is a central concept in precision oncology.
The analogy is simple: one "umbrella" (the overarching trial infrastructure) covers multiple "spokes" (sub-trials), each targeting a different molecular subset of patients with the same cancer.
Core Concept
| Feature | Description |
|---|---|
| Disease scope | Single cancer type (e.g., NSCLC, breast cancer) |
| Treatment arms | Multiple targeted therapies tested in parallel |
| Patient assignment | Based on molecular/biomarker profiling of the tumor |
| Infrastructure | Shared screening, data systems, genomic platforms |
| Trial phase | Mostly Phase I/II |
From Tietz Textbook of Laboratory Medicine, 7th Ed.: patients are assigned to a treatment arm "depending upon the mutation identified in each patient" - this is the defining principle of the umbrella design.
How It Differs from Basket Trials
| Umbrella Trial | Basket Trial |
|---|---|
| One cancer histology, multiple therapies | Multiple cancer types, one targeted therapy |
| Stratifies by molecular subtype within a disease | Groups by shared mutation across diseases |
| Example: Lung-MAP trial (NSCLC) | Example: BRAF V600E inhibitor across cancers |
Key Advantages
- Efficiency - Multiple treatment questions answered under one protocol, reducing cost and time vs. running separate trials
- Reduced patient numbers - Possible shared control arms avoid duplicating enrollment
- Molecular precision - Patients get therapies matched to their tumor's driver mutation
- Adaptive flexibility - Sub-trials can be added, modified, or dropped as new evidence emerges
- Access to novel therapies - Opens experimental treatments to patients whose tumors carry rare targetable mutations
Real-World Examples
- Lung-MAP (SWOG S1400) - The most prominent umbrella trial; patients with advanced squamous cell NSCLC are screened via a common genomic platform and assigned to biomarker-matched sub-studies testing different targeted agents
- NCI-MATCH (EAY131) - A large US national umbrella trial assigning patients to over 30 targeted therapy arms based on tumor mutation profiling
- DIAN-TU - A non-oncology umbrella trial in Alzheimer's disease, testing multiple biomarker-guided interventions
- TOZURA - Umbrella design applied to rheumatoid arthritis
Where It Is Used
According to a 2022 systematic review (PMC9596938), 92.1% of umbrella trials (35 of 38 identified) have been in oncology settings, mainly:
- Non-small cell lung cancer (most common)
- Breast cancer
Only 3 umbrella trials to date have been conducted outside oncology (HIV, Alzheimer's, rheumatoid arthritis) - but this may expand as precision medicine grows in other fields.
Statistical Considerations
Umbrella trials present unique design challenges:
- Whether to borrow information across sub-trials (often avoided since different drugs are tested)
- Bayesian vs. frequentist decision frameworks
- Sample size calculations for each molecular sub-group
- Controlling for multiple testing (family-wise error rate)
- Adaptive elements (dropping non-performing arms early)
Place in the Master Protocol Hierarchy
Master Protocols
├── Basket Trials — 1 therapy, multiple cancer types
├── Umbrella Trials — 1 cancer type, multiple therapies
└── Platform Trials — Continuous adaptive design; arms added/dropped flexibly
Key Takeaway
Umbrella trials represent a shift from the old "one disease, one drug" model to a "one disease, many molecular subtypes, many matched drugs" model. They are a foundational tool of precision oncology, allowing faster and more cost-effective evaluation of targeted therapies in genetically defined patient subgroups.
Relevant literature:
- Risk and benefit for umbrella trials - Systematic Review (PMID 35799149), BMC Med, 2022
- Design and analysis of umbrella trials - PMC review
- Umbrella trials systematic review - OCP
- Tietz Textbook of Laboratory Medicine, 7th Edition, Chapter 69 (Molecular subsets & targeted therapy assignment)
This is a shared conversation. Sign in to Orris to start your own chat.